Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial

Pieter F. de Groot(Amsterdam University Medical Centers), Max Nieuwdorp(Amsterdam Institute for Addiction Research), Lorenzo Piemonti(Vita-Salute San Raffaele University), Guido J. Bakker(Amsterdam UMC Location University of Amsterdam), Sytze van Dam(GGZ Oost Brabant), Martin N. Gerding(Deventer Ziekenhuis), Martin Diekman(Deventer Ziekenhuis), Elena Rampanelli(Amsterdam University Medical Centers), Antoinette M. Joosten, Valeria Sordi(Vita-Salute San Raffaele University), Gaby Duinkerken, Bart O. Roep(Immune Regulation (United Kingdom)), F. Holleman(Amsterdam University Medical Centers), Bartjan Potter van Loon, Nordin M.J. Hanssen(Foundation Centrum '45), Ilias Attaye(Amsterdam University Medical Centers), Aeilko H. Zwinderman(Amsterdam Neuroscience), Jacques Bergman(University of Amsterdam), Silvia Pellegrini(Vita-Salute San Raffaele University), Willem M. de Vos(University of Helsinki), Andrei Prodan(AstraZeneca (Netherlands)), C. van der Blij-de Brouwer(GGZ Oost Brabant), Daniël H. van Raalte(Amsterdam University Medical Centers), Sultan Imangaliyev(Amsterdam University Medical Centers), Victor E. A. Gerdes(Amsterdam UMC Location University of Amsterdam), Suat Şimşek(Northwest Hospital), Han Levels(Amsterdam University Medical Centers), Arianne van Bon(Rijnstate Hospital), Evgeni Levin(Horse Hospital), Cees Rustemeijer(Ziekenhuis Amstelland), Roel P.L.M. Hoogma(Groene Hart Ziekenhuis), Joost Hoekstra(Amsterdam University Medical Centers), Frank Stam(Noordwest Ziekenhuisgroep), Bernadette S. de Bakker(Amsterdam University Medical Centers)
Gut
October 26, 2020
Cited by 305


Related Papers